Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares are falling 16% after the biotech firm’s Phase 2 trial evaluating Selinexor in Older Patients with Relapsed Acute …
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) together with the Multiple Myeloma Research Foundation (MMRF) announced that Karyopharm will host an investor and analyst dinner reception …
Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced that preclinical and Phase 1 clinical data describing XPO1 inhibition with selinexor (KPT-330), the Company’s lead, oral Selective Inhibitor …
Karyopharm Therapeutics Inc (NASDAQ:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from its Phase 2b STORM study evaluating the activity of selinexor …
Karyopharm Therapeutics Inc (NASDAQ:KPTI), a clinical-stage pharmaceutical company, today announced a poster presentation highlighting updated clinical data from the Company’s ongoing Phase 1b …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares closed down about 13% after the company announced a proposed public offering of its common stock yesterday.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced the presentation of clinical data for its lead drug candidate, selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of …
Karyopharm Therapeutics Inc (NASDAQ:KPTI) a clinical-stage pharmaceutical company, today reported that its SINE™ nuclear transport compounds are being evaluated for the treatment of …
In a research report issued today, J.P.
In a research report released today, MLV analyst Arlinda Lee maintained a Buy rating on shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI), and reduced the …
